Results

Total Results: 129 records

Showing results for "venous".

41. Evidence Summary: Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/vitamin-d-calcium-or-combined-supplementation-for-the-primary-prevention-of-fractures-in-adults-preventive-medication
    April 17, 2018 - incident kidney stones, incident cancer, and incident cardiovascular disease (including stroke and venous … 0.47%]; HR, 0.90 [95% CI, 0.54 to 1.50]). 17 Similar, nonsignificant findings were found for stroke, venous … 0.11% [95% CI, −0.20% to 0.41%]; HR, 1.03 [95% CI, 0.90 to 1.19]). 29 Similar findings for stroke, venous … were also reported (stroke: ARD, −0.09% [95% CI, −0.38% to 0.20%] and HR, 0.95 [95% CI, 0.82 to 1.10]; venous … The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism: from the

42. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/v7w4xaGG822hVc_SCU3tQ_
    November 01, 2022 - progestin is associated with moderate harms, including increased risk of invasive breast cancer, stroke, venous … evidence that use of estrogen alone is associated with moderate harms, including increased risk of stroke, venous … In the WHI (n = 16 608), persons randomized to estrogen plus progestin had an increased risk of venous … Estrogen plus progestin and risk of venous thrombosis.

43. Recommendation: Latent Tuberculosis Infection in Adults: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/latent-tuberculosis-infection-screening
    May 02, 2023 - The IGRA requires a single venous blood sample that measures the CD4 T-cell response to specific Mycobacterium … protein derivative and interpret the response 48 to 72 hours later. 25 , 27 The IGRA requires a single venous … Screening with an IGRA requires obtaining a single venous blood sample, and patients do not need to return … However, clinicians should be aware of processing requirements for blood samples and ensure that venous

44. Final Research Plan: Hormone Therapy in Postmenopausal Persons: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/menopausal-hormone-therapy-preventive-medication
    May 27, 2021 - with contraindications for HT use such as history of breast cancer, coronary heart disease, a previous venous

45. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/V7SNHdqvUyT7e2hQt5HbFp
    December 12, 2017 - for gallbladder disease (30 more cases [95% CI, 16 to 48]), stroke (11 more cases [95% CI, 2 to 23]), venous … (9 more cases [95% CI, 2 to 19]), urinary incontinence (876 more cases [95% CI, 606 to 1168]), and venous … Venous thrombosis and conjugated equine estrogen in women without a uterus. … Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the … Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573-1580. 56.

46. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/KdQef_VDT2kmHDX4ddNWmR
    August 01, 2022 - ° The IGRA requires a single venous blood sample that measures the CD4 T-cell response to specific … protein derivative and interpret the response 48 to 72 hours later.25,27 The IGRA requires a single venous … Screening with an IGRA requires obtaining a single venous blood sample, and patients do not need to return … However, clinicians should be aware of processing require- ments for blood samples and ensure that venous

47. VitaminD, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/Yc24U4wMLXGoqE5NjwRVA6
    April 17, 2018 - i d e n t c a n c e r, a n d i n c i d e n t c a r d i o va s - cular disease (including stroke and venous … 0.47%]; HR, 0.90 [95% CI, 0.54 to 1.50]).17 Similar, nonsignificant findings were found for stroke, venous … , 0.11% [95% CI, −0.20% to 0.41%]; HR, 1.03 [95% CI, 0.90 to 1.19]).29 Similar findings for stroke, venous … 95% CI, 0.90 to 1.19) Stroke: ARD, −0.09% (95% CI, −0.38% to 0.20%); HR, 0.95 (95% CI, 0.82 to 1.10) Venous … The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism: from the

48. Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/Njxn2r3qtWKdBf2_VhS2Aw
    April 01, 2016 - CVD = cardiovascular disease; DAMAD = Dipyridamole Aspirin Microangiopathy of Diabetes; DVT = deep venous … Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979- 87. … Atherosclerosis; AMIS = Aspirin Myocardial Infarction Study; ASPIRE = Aspirin to Prevent Recurrent Venous … for Asymptomatic Atherosclerosis; ABI = ankle–brachial index; ASPIRE = Aspirin to Prevent Recurrent Venous … Thromboembolism; BMD = British Male Doctors; CVD = cardiovascular disease; DVT = deep venous thrombosis

49. Screening for Lipid Disorders in Children: Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/BwAo_shwmJLSRguyWxaXpP
    July 01, 2007 - treatment in children. 3 Accuracy of Screening Tests TC and HDL-C can be measured on nonfasting venous … samples, LDL-C measurement requires fasting samples, and direct LDL-C can be measured on nonfasting venous

50. Archived: Latent Tuberculosis Infection: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/latent-tuberculosis-infection-screening-september-2016
    September 06, 2016 - Interferon-gamma release assays require a single venous blood sample and laboratory processing within … the test results within the proper time frame. 26 Screening with an IGRA requires obtaining a single venous … However, clinicians should be aware of processing requirements for blood samples and ensure that venous

51. Archived: Lipid Disorders in Children: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/lipid-disorders-in-children-screening-2007
    July 15, 2007 - Accuracy of Screening Tests TC and HDL-C can be measured on nonfasting venous or capillary blood samples … , LDL-C requires fasting samples, and direct LDL-C can be measured on nonfasting venous samples.

52. Screening for Latent Tuberculosis Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/Wx_w92ukxeDvNShoRQXbhP
    September 06, 2016 - Interferon-gamma release assays require a single venous blood sample and laboratory processing within … the test results within the proper time frame.26 Screening with an IGRA requires obtaining a single venous … However, clinicians should be aware of processing requirements for blood samples and ensure that venous

53. Evidence Summary: Breast Cancer: Medication Use to Reduce Risk | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-cancer-medications-for-risk-reduction
    September 03, 2019 - first 3 years of tamoxifen use. 111 Age older than 60 years was also an important risk factor for venous … 95% CI, 1.03-1.80]) and stroke (odds ratio, 3.36 [95% CI, 1.04-14.18]) with anastrozole and increased venous … also indicated associations with increased fractures for aromatase inhibitors but no differences for venous … Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. … with tamoxifen 0.97 (0.86-1.12) 2 NA NA 1.05 (0.87-1.28) 2 NA NA Harms Venous

54. Screening for Elevated Blood Lead Levels in Childhood and Pregnancy: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/-TJhx6cZFX9K7RoDQJNcM6
    November 18, 2016 - CI, 31.4% to 65.6%) and specificity of 58% (95% CI, 39.9% to 74.0%) for identifying children with a venous … lead testing demonstrated sensitivity of 87% to 91% and specificity greater than 90%, compared with venous … Testing approaches included stud- ies of screening questionnaires and venous or capillary blood lead … for KQ1 were screening vs no screening; for KQ2a, a questionnaire against a reference standard (ie, venous … lead level); for KQ2b, capillary vs venous blood lead level testing; and for treatment questions, treatment

55. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/-TsBkyewVoFpC7htRmzWJa
    September 03, 2019 - PE, pulmonary embolism; RR, risk ratio; RUTH, Raloxifene Use for the Heart; SE, standard error; VTE, venous … the first 3 years of tamoxifen use.111 Age older than 60 years was also an important risk factor for venous … CI, 1.03- 1.80]) and stroke (odds ratio, 3.36 [95% CI, 1.04-14.18]) with anastrozole and increased venous … also indicated associations with increased fractures for aromatase inhibitors but no differences for venous … Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.

56. Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction-2013
    September 15, 2013 - Risk Reduction The USPSTF found adequate evidence that tamoxifen and raloxifene increase risk for venous … tamoxifen nor raloxifene should be used in women who have a history of thromboembolic events (deep venous … Women with a personal or family history of venous thromboembolism are at higher risk for these adverse … Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.

57. Zvvry6Wa4Sgj-Ejb3Brcvy (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/zVVRY6wa4Sgj-EJb3BRcVy
    November 01, 2013 - Risk Reduction The USPSTF found adequate evidence that tamoxifen and raloxifene increase risk for venous … tamoxifen nor raloxifene should be used in women who have a history of thrombo- embolic events (deep venous … Women with a personal or family history of venous thromboembolism are at higher risk for these ad- verse … Effect of tamoxifen on venous thrombo- embolic events in a breast cancer prevention trial.

58. Archived: Iron Deficiency Anemia in Pregnant Women and Young Children: Screening and Supplementation, 1996 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/iron-deficiency-anemia-pregnant-women-young-children-screening-supplementation-1996
    January 01, 1996 - for infant testing, results obtained from capillary blood specimens are less reliable than those from venous … microhematocrit to have a sensitivity of 90% and a specificity of 44% when compared with values obtained from venous … Although capillary blood specimens are easier to obtain in infants, a venous blood count provides more

59. Archived: Evidence Summary: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary27/breast-cancer-medications-for-risk-reduction-2013
    April 15, 2013 - A recent meta-analysis of tamoxifen trials indicated that risks for endometrial cancer, deep venous thrombosis … women indicated that breast cancer (69%), pulmonary embolism (67%), endometrial cancer (63%), and deep venous … Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention … Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. … 1.67) ¶¶ 3 - - 0.93 (0.84–1.04) 2 - - CHD = coronary heart disease; DVT = deep venous

60. Final Recommendation Statement: Breast Cancer: Medication Use to Reduce Risk | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/breast-cancer-medications-for-risk-reduction
    September 03, 2019 - Tamoxifen and raloxifene increase risk for venous thromboembolic events (VTEs); tamoxifen increases risk … Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. … Nonvertebral 3 (0.2-5) ND ND Harms: Events Increased (95% CI) a Vascular    Venous